Prolonged postoperative length of stay may be a valuable marker for susceptibility to relapse beyond established risk factors in patients with stage III colon cancer

Frans Emland1, Helena Taflin2, Göran Carlsson3,4, David Ljungman3,4 and Elinor Bexe Lindskog3,4*

Abstract

Background: Delay from surgery to adjuvant chemotherapy causes impaired survival among patients undergoing radical resection for stage III colon cancer, and the underlying mechanism for this is incompletely clarified. It is established that prolonged postoperative hospital length of stay (LOS) is associated with delayed initiation of the adjuvant treatment driving the assumption that prolonged LOS is prognostically unfavorable due to this fact and case mix factors. We hypothesize that prolonged LOS after surgery is a valuable marker for susceptibility to relapse that is not detected in established prognostic factors and, alone, associated with a shorter disease-free survival (DFS).

Materials and methods: A total of 690 consecutive patients undergoing elective radical resection for stage III colon cancer in 2000–2015 were identified in a prospective detailed facility database. Univariate and multivariate analyses were performed using Cox proportional hazards model in the evaluation of LOS as an independent prognostic factor.

Results: Short postoperative LOS, low comorbidity, and few complications were associated with longer DFS (p < 0.01). Fewer patients in the short and intermediate LOS groups had a relapse in their disease (28% and 33%, respectively), compared to the patients with longer LOS (40%, p < 0.05). LOS was a prognostic factor for DFS in the unadjusted univariate model (HR 1.04 per unit change) and remained statistically significant in the adjusted multivariate analysis, with a HR of 1.03 per hospital day (p < 0.01).

Conclusions: Postoperative LOS independently correlates with the risk of recurrence and DFS, regardless of if adjuvant chemotherapy is given, along with the factors such as age, comorbidity, complications, and tumor features. We propose a further investigation into the causal mechanisms based on tumor and host biology linking LOS to DFS beyond established risk factors.

Keywords: Colonic neoplasm, Postoperative length of stay, Prognostic risk factor, Disease-free survival

Background

Colorectal cancer (CRC) is the third most common form of cancer in the world, and around two-thirds of these consist of colon cancer [1]. Surgery remains the basis for curative treatment, while chemotherapy is recommended for all patients with stage III colon cancer without contraindications to reduce the risk of recurrence after radical surgery [2, 3]. The benefit of adjuvant treatment still
varies within stage III, emphasizing the importance of individual risk stratification [3, 4].

Both enhanced recovery care and laparoscopy have become the crucial parts of the perioperative care of patients with colon cancer, consequently reducing the postoperative LOS [5–7]. The strongest predictive factors for a prolonged LOS are postoperative reoperations, infections at the surgical site, and open surgery in contrast to laparoscopic surgery [8].

Adjuvant chemotherapy should be initiated close in time to surgery and at the latest within 8 weeks for the best effect [3, 9, 10]. A contributing factor to delayed adjuvant chemotherapy is prolonged LOS, consequently associating prolonged LOS with a worse outcome [11].

Delayed adjuvant chemotherapy has in many studies been shown to shorten both DFS and overall survival (OS) [9, 10]. It is yet, to our knowledge, not known if prolonged LOS alone correlates with the oncological outcome. While just a few studies have been carried out on this issue, findings are hampered by the incoherent composition of the cohorts: studying colon and rectal cancer patients, mixed stages, and with no relation to adjuvant chemotherapy [12, 13].

The rationale behind this study lies within the fact that delayed adjuvant chemotherapy is prognostically unfavorable, while the underlying mechanism for this is incompletely clarified. Tumor immunological factors affecting minimal residual disease in patients treated for stage III colon cancer could be hidden in the LOS, encouraging the present study to evaluate if prolonged LOS is of prognostic value.

Tumor biology is of great importance for prognosis and survival but has little impact on decisioning on adjuvant chemotherapy. In the clinical setting age, comorbidity, postoperative convalescence, and by extension LOS are the main factors determining if, and when, a patient is eligible for adjuvant chemotherapy. A postponed postoperative follow-up, caused by prolonged LOS, risks ruling out or delaying the adjuvant chemotherapy. The aim of the present study is to investigate how postoperative hospital LOS independently impacts the prognosis of patients treated for stage III colon cancer, in relation to adjuvant chemotherapy.

**Material and methods**

**Study design and population**

All patients in this study have undergone surgery for stage III colon cancer at Sahlgrenska University Hospital (SU) between the years 2000 and 2015. We included only stage III to have a homogenous cohort where the group at large is recommended adjuvant chemotherapy. The inclusion criteria for participating in the study were elective surgery, microscopic radical resection, and at least 90 days of postoperative survival. The study period was set to include the 5-year follow-up; 6 patients were lost to follow-up and thereby excluded. Full analyses were performed in a cohort of 690 patients. Length of stay (LOS) was defined as the number of days spent in the hospital from the day of surgery until discharge.

The endpoint in the study was disease-free survival (DFS), defined as the time from radical surgery to an event. Local or distal recurrence, all-cause mortality, or new CRC were all classified as events. Patients were censored if lost to follow-up or living without disease at the end of the study period. DFS was favored above other outcome measures, due to the nature of this study and considering the variables being investigated. The overall survival (OS) includes more confounding factors and more to take into consideration, for example, whether a patient with recurrence receives first-, second-, or third-line chemotherapy, as well as if the patient goes through new potentially curable surgery.

Comorbidity, postoperative complications, LOS, any reinterventions, and readmissions were collected through medical records. Comorbidities were assessed by the age-adjusted Charlson Comorbidity Index (ACCI) [14] and postoperative complications according to the Clavien-Dindo (CD) classification [15]. Using ACCI, every decade above 40 years is given 1 point; hence, age is adjusted in the final analysis. ACCI were grouped into low (0–2 points), intermediate (3–5 points), and high (6–9 points). Clavien-Dindo was dichotomized into minor (grade 0–3a) and major (grade 3b–4) complications.

**Statistical analysis**

All statistical analyses were carried out by the statistical software JMP®, version 15.0.0, for Macintosh (SAS Institute Inc., Cary, NC). The significance level was set to a two-sided p-value of < 0.050. As quantitative data, such as age, had a skewed distribution, they are presented with a median value together with the minimum and maximum value or the measure of variability, interquartile range (IQR), and statistical significance tested with the nonparametric Wilcoxon test. Qualitative variables at the nominal level, for example, tumor location, are presented as frequencies and percentages, and Pearson’s chi-squared test was used for significance testing.

Univariate analyses were carried out for specific parameters, using Cox proportional hazards model to assess which factors were influencing the DFS. A multivariate model was constructed, with adjustment for possible confounders in the assessment of LOS as an independent prognostic factor for DFS.
Results
In the entire cohort of 690 patients, the median age was 71 years, and a narrow majority of patients were female (54%). Patients were distributed as evenly as possible into three groups according to their LOS, in order to analyze how different clinical characteristics were associated with a longer LOS: shorter (≤5 days), intermediate (6–8 days), and prolonged (>8 days) postoperative hospital stay. A full description of the clinical characteristics of the three LOS cohorts is presented in Table 1.

Clinical characteristics related to length of stay
As shown in Table 1, the tumor-specific factors did not significantly differ between the LOS groups. Also, there was no difference in readmission rates between the different LOS groups and neither did comorbidity or age impact the risk of readmission. Though, patients with major complications (Clavien-Dindo 3b–4) had a higher rate of readmissions, 15% compared to 6% (p < 0.05).

Comorbidity and major postoperative complications were more common in the longer LOS group. Patients in the high comorbidity group (ACCI 6–9) had a mean LOS of 11.8 days compared to 7.9 days in the group with no or little comorbidity (ACCI 0–2) (p < 0.01). As expected, the 46 cases with major postoperative complications (Clavien-Dindo 3b–4) had a significantly longer LOS compared to those with no or minor complications (Clavien-Dindo 0–3a) (p < 0.01).

The median LOS in the hospital was 7 days with no difference over the years studied (p > 0.05) despite increased utilization of laparoscopic surgery during the years. Only 2 out of 42 patients (5%) had laparoscopic surgery in the year 2000 compared to 26 out of 56 (46%) in 2015 (p < 0.01). However, the frequency of T4 tumors increased, involving only 5 out of 42 (12%) operated tumors in 2000 to 14 out of 56 in 2015 (25%) (p < 0.01). There was no statistically significant difference in age or comorbidity (ACCI) over the studied period (p > 0.05).

Factors influencing adjuvant chemotherapy
Fewer patients in the group with prolonged LOS received adjuvant chemotherapy (<0.01, Table 1). Conversely, patients who received adjuvant chemotherapy had a shorter LOS (p < 0.01, Table 2). In total, 434 patients (63%) received adjuvant chemotherapy, where 69% of these received a single treatment with 5-fluorouracil (5-FU) together with leucovorin (FLV) and 31% were treated with a combination chemotherapy. The time from surgery to the initiation of adjuvant chemotherapy varied between the different LOS groups (p=0.01). The proportion of patients in the long LOS group with a late start (>8 weeks) of adjuvant chemotherapy was higher (p < 0.05), and patients with a late start also had a longer mean LOS (p < 0.01, Additional file 1: Table S1).

Patients who received adjuvant chemotherapy were younger (p < 0.01, Table 2). In the age group 60 years or younger, 94% received adjuvant treatment, 88% among patients aged 61–70, and 35% in patients 71 years or older (p < 0.01). Among patients with no or low comorbidity (ACCI 0–2), 95% received adjuvant chemotherapy, 47% among patients with intermediate comorbidity (ACCI 3–5), and 15% in the high comorbidity group (ACCI 6–9) (p < 0.01). Major postoperative complications did not affect whether the patients received adjuvant chemotherapy, neither was there a difference in single or combination treatment in relation to major postoperative complications (Clavien-Dindo 0–3a or 3b–4).

The frequency of combination chemotherapies carried out and the timing of the adjuvant treatment changed during the studied period (p < 0.01). Only 4 out of 26 (15%) received combination chemotherapy in 2000 and 12 (46%) within 8 weeks. In 2015, 15 out of 33 (45%) received combination chemotherapy and 32 (97%) within 8 weeks. In total, more patients received combination therapy starting within 8 weeks compared to those who started after 8 weeks (p < 0.01, Additional file 1: Table S1).

Postoperative hospital length of stay and outcomes
Among the 690 patients who underwent radical surgery for stage III colon cancer between the years 2000–2015, 34% (n = 234) relapsed in their disease, and 50% (n = 342) had any of the defined events (local or distal recurrence, all-cause mortality, or new CRC) (Table 3). Among the patients who had any of the defined events, the mean LOS was 10.0 days compared to 7.7 days in the censored group (p < 0.01). Fewer patients in the short and intermediate LOS groups had a relapse in their disease (28% and 33%, respectively), compared to the patients with longer LOS (40%, p < 0.05). There was no statistically significant difference in terms of postoperative complications or comorbidity as to whether the patients had a relapse in their disease or not.

Furthermore, patients in the short and intermediate LOS groups were less likely to have any of the defined events (38% and 46%, respectively), compared to the patients with longer hospital LOS (63%, p < 0.01). Patients who had a relapse in their disease also had a longer mean LOS than patients without relapse, 9.5 days compared to 8.5 days (p < 0.05). Out of the whole cohort, 11% (n = 76) relapsed within 1 year from surgery. These patients had a mean LOS of 10.4 days, compared to 9.1 days among patients relapsing after 1 year and 8.5 days in patients who remained relapse-free (p < 0.05).
### Table 1: Clinical characteristics of stage III colon cancer patients by hospital length of stay cohorts

| Variables                      | Length of stay (days)               | p-value | Total (n = 690) |
|--------------------------------|-------------------------------------|---------|-----------------|
|                                | ≤ 5 (n = 202) | 6–8 (n = 248) | > 8 (n = 240)  |                      |
| Length of stay (days)          |          |           |              |                      |
| Median (min-max)               | 5 (3–5)  | 7 (6–8)  | 12 (9–51)    | 7 (3–51)            |
| Mean                           | 4.5      | 6.9      | 14.5         | 8.8                 |
| Age, median (min-max)          | 69 (27–92)| 69 (19–91)| 73 (19–93)   | < 0.05              |
| Gender,n(%)                   |          |           |              |                      |
| Female                        | 106 (52) | 145 (58) | 124 (52)     | NS                  |
| Male                          | 96 (48)  | 103 (42) | 116 (48)     | 315 (46)            |
| Surgery,n(%)                  |          |           |              |                      |
| Open                           | 142 (70)| 221 (89) | 222 (93)     | < 0.01              |
| Laparoscopic                   | 60 (30)  | 27 (11)  | 18 (8)       | 105 (15)            |
| Tumor location,n(%)           |          |           |              |                      |
| Right sided                   | 113 (56)| 134 (54) | 121 (50)     | NS                  |
| Left sided                    | 88 (44) | 113 (46) | 112 (47)     | 313 (45)            |
| Multiple locations            | 1 (1)    | 1 (0)    | 7 (3)        | 9 (1)               |
| Differentiation grade,n(%)    |          |           |              |                      |
| Low grade (G1–G2)             | 142 (70)| 172 (69) | 169 (70)     | NS                  |
| High grade (G3–G4)            | 47 (23) | 63 (25)  | 58 (24)      | 168 (24)            |
| Mucinous                      | 13 (6)  | 13 (5)   | 13 (5)       | 39 (6)              |
| T-stage,n(%)                  |          |           |              |                      |
| 1                              | 5 (2)    | 2 (1)    | 3 (1)        | NS                  |
| 2                              | 14 (7)   | 16 (6)   | 14 (6)       | 44 (6)              |
| 3                              | 150 (74)| 178 (72)| 159 (66)     | 487 (71)            |
| 4                              | 33 (16) | 52 (21)  | 64 (27)      | 149 (22)            |
| N-stage,n(%)                  |          |           |              |                      |
| N1                             | 136 (67)| 152 (61)| 158 (66)     | NS                  |
| N2                             | 66 (33) | 96 (39)  | 82 (34)      | 244 (35)            |
| Adjuvant chemotherapy,n(%)    |          |           |              |                      |
| Yes                            | 140 (69)| 169 (68)| 125 (52)     | < 0.01              |
| No                             | 62 (31) | 79 (32)  | 115 (48)     | 256 (37)            |
| Timing of adjuvant chemotherapy,n(%) | | | | |
| < 8 weeks                      | 59 (42) | 72 (43) | 36 (29)      | < 0.05              |
| > 8 weeks                      | 81 (58) | 97 (57) | 89 (71)      | 267 (62)            |
| ACCI,n(%)                      |          |           |              |                      |
| 0–2                            | 89 (44) | 104 (42)| 69 (29)      | < 0.01              |
| 3–5                            | 107 (53)| 127 (51)| 142 (59)     | 376 (54)            |
| 6–9                            | 6 (3)   | 17 (7)   | 29 (12)      | 52 (8)              |
| Clavien-Dindo,n(%)             |          |           |              |                      |
| 0–3a                           | 202 (100)| 239 (96)| 203 (85)     | < 0.01              |
| 3b–4                           | –       | 9 (4)    | 37 (15)      | 46 (7)              |
| Readmission,n(%)               |          |           |              |                      |
| No                             | 189 (94)| 229 (92)| 225 (94)     | NS                  |
| Yes                            | 13 (6)  | 19 (8)   | 15 (6)       | 47 (7)              |

Percentages within the parentheses should be read vertically, representing the top subject

**Abbreviations:** IQR interquartile range, ACCI age-adjusted Charlson Comorbidity Index, NS not significant.

* Percentage does not add up due to rounding

* Within 30 days
Patients with a short postoperative hospital LOS, low comorbidity, and few complications had a longer unadjusted DFS ($p < 0.01$, Fig. 1). The cohort with prolonged LOS had significantly shorter DFS compared to the cohorts with short and intermediate LOS (unadjusted HR 2.10 and 1.58, respectively, $p < 0.01$). Furthermore, without categorizing, postoperative hospital LOS was a significant prognostic factor for DFS when considered as a continuous variable in the unadjusted univariate model (HR 1.04 per unit change, Table 4). In the adjusted multivariate analysis, LOS remained statistically significant, with a HR of 1.03 per hospital day ($p < 0.01$).

Table 2  Clinical characteristics of stage III colon cancer patients by adjuvant chemotherapy

| Variables                              | Adjuvant chemotherapy | $p$-value | Total ($n = 690$) |
|----------------------------------------|-----------------------|-----------|-------------------|
|                                        | Yes ($n = 434$)       | No ($n = 256$) |
| Hospital length of stay, days          |                       |           |                   |
| Median (IQR)                           | 7 (5–9)               | 8 (6–13) | $< 0.01$          |
| Mean (SD)                              | 8.0 (5.1)             | 10.2 (6.8)| $< 0.01$          |
| Age, median (min-max)                  | 65 (19–83)            | 81 (41–93)| $< 0.01$          |
| Gender, $n$(%)                         |                       |           |                   |
| Female                                 | 221 (51)              | 154 (60) | $< 0.05$          |
| Male                                   | 213 (49)              | 102 (40) | 375 (54)          |
| Surgery, $n$(%)                        |                       |           |                   |
| Open                                   | 368 (85)              | 217 (85) | NS                |
| Laparoscopic                           | 66 (15)               | 39 (15)  | 105 (15)          |
| Tumor location, $n$(%)$^a$             |                       |           |                   |
| Right sided                            | 216 (50)              | 152 (59) | NS                |
| Left sided                             | 212 (49)              | 101 (39) | 313 (45)          |
| Multiple locations                     | 6 (1)                 | 3 (1)    | 9 (1)             |
| Differentiation grade, $n$(%)          |                       |           |                   |
| Low grade (G1–G2)                      | 308 (71)              | 175 (68) | NS                |
| High grade (G3–G4)                     | 105 (24)              | 63 (25)  | 168 (24)          |
| Mucinous                               | 21 (5)                | 18 (7)   | 39 (6)            |
| Number of positive lymph nodes, median (IQR) | 3 (1–5)               | 2 (1–4)  | $< 0.01$          |
| T-stage, $n$(%)                        |                       |           |                   |
| 1                                      | 8 (2)                 | 2 (1)    | $< 0.05$          |
| 2                                      | 28 (6)                | 16 (6)   | 44 (6)            |
| 3                                      | 291 (67)              | 196 (77) | 487 (71)          |
| 4                                      | 107 (25)              | 42 (16)  | 149 (22)          |
| N-stage, $n$(%)                        |                       |           |                   |
| N1                                     | 268 (62)              | 178 (70) | $< 0.05$          |
| N2                                     | 166 (38)              | 78 (30)  | 244 (35)          |
| ACCI, $n$(%)$^a$                       |                       |           |                   |
| 0–2                                    | 250 (58)              | 12 (5)   | $< 0.01$          |
| 3–5                                    | 176 (41)              | 200 (78) | 376 (54)          |
| 6–9                                    | 8 (2)                 | 44 (17)  | 52 (8)            |
| Clavien-Dindo, $n$(%)                  |                       |           |                   |
| 0–3a                                   | 407 (94)              | 237 (93) | NS                |
| 3b–4                                   | 27 (6)                | 19 (7)   | 46 (7)            |
| Readmission, $n$(%)                    |                       |           |                   |
| No                                     | 403 (93)              | 240 (94) | NS                |
| Yes                                    | 31 (7)                | 16 (6)   | 47 (7)            |

Percentages within the parentheses should be read vertically, representing the top subject

Abbreviations: IQR interquartile range, ACCI age-adjusted Charlson Comorbidity Index, NS not significant

$^a$ Percentage does not add up due to rounding
Comorbidities were also associated with a higher risk of the events (HR 1.59 in ACCI 3–5 and 2.40 in ACCI 6–9). Although significant in the univariate analysis, major postoperative complications (Clavien-Dindo grade) did not reach statistical significance in the multivariate model. A comparison of DFS among the LOS groups related to receiving adjuvant chemotherapy, in addition to no treatment at all, is shown in Fig. 2. As illustrated, DFS is shorter in the longer LOS groups, regardless of if adjuvant chemotherapy was given or not.

### Table 3  Clinical characteristics of stage III colon cancer patients by disease recurrence

| Variables                              | Disease recurrence | p-value | Total (n = 690) |
|----------------------------------------|--------------------|---------|-----------------|
|                                        | Yes (n = 234)      |         |                 |
|                                        | No (n = 456)       |         |                 |
|                                        | p-value            |         |                 |
| Hospital length of stay, days          |                    |         |                 |
| Median (IQR)                           | 7.5 (6–11)         | < 0.05  | 7 (5–10)        |
| Mean (SD)                              | 9.5 (6.6)          | < 0.05  |                 |
| Age, median (min-max)                  | 70 (25–93)         |         | 71 (19–93)      |
| Gender, n(%)                           | Female             | NS      | 375 (54)        |
|                                        | Male               | NS      | 315 (46)        |
| Surgery, n(%)                          | Open               | NS      | 585 (85)        |
|                                        | Laparoscopic       | NS      | 105 (15)        |
| Tumor location, n(%)                   | Right sided        | NS      | 368 (53)        |
|                                        | Left sided         | NS      | 313 (45)        |
|                                        | Multiple locations | NS      | 9 (1)           |
| Differentiation grade, n(%)            | Low grade (G1–G2)  | NS      | 483 (70)        |
|                                        | High grade (G3–G4) | NS      | 168 (24)        |
|                                        | Mucinous           | NS      | 39 (6)          |
| Number of positive lymph nodes, median (IQR) | 3.5 (2–6)         | < 0.01  | 2 (1–5)         |
| T-stage, n(%)                          | 1                  | < 0.01  | 10 (1)          |
|                                        | 2                  |         | 44 (6)          |
|                                        | 3                  |         | 487 (71)        |
|                                        | 4                  |         | 149 (22)        |
| N-stage, n(%)                          | N1                 | < 0.01  | 446 (65)        |
|                                        | N2                 |         | 244 (35)        |
| ACCI, n(%)                             | 0–2                | NS      | 262 (38)        |
|                                        | 3–5                |         | 376 (54)        |
|                                        | 6–9                |         | 52 (8)          |
| Clavien-Dindo, n(%)                    | 0–3a               | NS      | 644 (93)        |
|                                        | 3b–4               |         | 46 (7)          |
| Readmission, n(%)                      | No                 | NS      | 643 (93)        |
|                                        | Yes                |         | 47 (7)          |

Percentages within parentheses should be read vertically, representing the top subject

*Abbreviation: IQR interquartile range, ACCI Age–Adjusted Charlson comorbidity index, NS not significant

* Percent do not add up due to rounding
Receiving adjuvant chemotherapy after 8 weeks, compared to within 8 weeks, was associated with a shorter DFS (HR 1.55, \( p < 0.01 \)). Patients who received adjuvant chemotherapy within 8 weeks after surgery had fewer recurrences compared to those who commenced later than 8 weeks, 28% and 37%, respectively (\( p < 0.05 \)). However, no significant difference in DFS was shown once comparing adjuvant chemotherapy within or after 8 weeks, when distributed on the different LOS groups. Nevertheless, patients who did not receive adjuvant chemotherapy at all had a significantly shorter DFS in the longer LOS groups.

**Discussion**

To our knowledge, this is the first study evaluating the association between prolonged postoperative hospital LOS and shorter DFS among patients undergoing radical resection of stage III colon cancer. In this detailed assessment, we have excluded confounding factors such as rectal tumors, other stages, emergency surgery, and postoperative mortality.

There are several studies conducted on what causes prolonged LOS in colorectal patients and its relations to other factors, such as comorbidity and complications. However, there are very few reports on how longer LOS affects the oncological outcome after surgery for colon cancer. Tartter concluded in 1996 that longer postoperative hospital LOS led to impaired survival for patients undergoing surgery for colorectal cancer [12]. Similarly, Shin et al. reported in 2017 that reduced postoperative hospital LOS led to improved survival among patients aged \( \geq 70 \) years [13]. Within this study, we intentionally excluded rectal cancer patients whose LOS is known to be longer [7, 16]. Another unique characteristic of the present study is that we have put LOS in relation to adjuvant chemotherapy, only including stage III since the benefit of adjuvant chemotherapy is greater among this group in contrast to CRC at large [3, 4].

Many reports have concluded the association between delayed initiation of adjuvant treatment and a decreased OS and DFS [9, 10, 17], supporting prolonged LOS as an independent risk factor, since longer LOS after surgery causes delayed commencement of adjuvant chemotherapy [11]. Our study confirmed that an extended period from surgery to adjuvant treatment increased the risk of a shorter DFS, as well as the association between longer LOS and delayed initiation. Furthermore, patients with a prolonged LOS were less likely to receive adjuvant treatment compared to those with a shorter stay. As expected, adjuvant chemotherapy increased DFS in our study—however, prolonged LOS was still associated with a shorter DFS among patients who did not receive adjuvant treatment at
all. Hence, it can be assumed that the shorter DFS among patients with longer LOS is not solely explained by delay or failure to receive adjuvant chemotherapy.

Previous studies have reported postoperative complications to be associated with a higher risk of recurrences and a worse overall survival, among patients undergoing surgery for colorectal cancer [18–20], and an especially strong relationship with anastomotic leakage [21–23]. Similar associations have been made for comorbidity, where cancer-specific survival has shown to be shorter [24, 25]. In the present study, both major postoperative complications and comorbidity were associated with a shorter DFS in the univariate analysis, but the results were not maintained for postoperative complications in the multivariate analysis. Neither did we find any correlation between postoperative complications and an increased risk for recurrence of the disease. This could perhaps partly be explained by the fact that the patients with postoperative complications received adjuvant chemotherapy to the same extent as those with a complication-free hospital stay. However, it may also be due to the relatively small sample size of major complications. In any case, comorbidity and postoperative complications cannot help to explain the elevated risk of recurrence we found among

Table 4  Complete case multivariate Cox proportional hazards model for disease-free survival

| Variables                     | Univariate |          |          |          | Multivariate |          |          |
|-------------------------------|------------|----------|----------|----------|--------------|----------|----------|
|                               |            | HR 95% CI| p        | HR 95% CI| p            | HR 95% CI| p        |
| Gender                        |            |          |          |          |              |          |          |
| Female                        | 1          |          |          |          |              |          |          |
| Male                          | 1.13       | 0.92–1.40| NS       | 0.77     | 0.55–1.06 NS  |          |          |
| Surgery                       |            |          |          |          |              |          |          |
| Open                          | 1          |          |          | 1        |              |          |          |
| Laparoscopic                  | 0.68       | 0.49–0.94| < 0.05   | 0.77     | 0.55–1.06 NS  |          |          |
| T-stage                       |            |          |          |          |              |          |          |
| T1–T3                         | 1          |          |          | 1        |              |          |          |
| T4                            | 1.33       | 1.04–1.71| < 0.05   | 1.26     | 0.98–1.63 NS  |          |          |
| N-stage                       |            |          |          |          |              |          |          |
| N1                            | 1          |          |          | 1        |              |          |          |
| N2                            | 1.59       | 1.28–1.97| < 0.01   | 1.60     | 1.29–2.00 < 0.01 |          |          |
| Differentiation               |            |          |          |          |              |          |          |
| High (G1–G2)                  | 1          |          |          | 1        |              |          |          |
| Low (G3–G4)                   | 1.16       | 0.91–1.49| NS       | 1.60     | 1.29–2.00 < 0.01 |          |          |
| Mucinous                      | 1.25       | 0.80–1.95| NS       | 1.59     | 1.20–2.11 < 0.01 |          |          |
| Tumor location                |            |          |          |          |              |          |          |
| Right sided                   | 1          |          |          | 1        |              |          |          |
| Left sided                    | 0.88       | 0.71–1.09| NS       | 1.07     | 0.70–1.63 NS  |          |          |
| Multiple locations            | 0.75       | 0.28–2.03| NS       |          |              |          |          |
| Adjuvant chemotherapy         |            |          |          |          |              |          |          |
| Yes                           | 1          |          |          | 1        |              |          |          |
| No                            | 2.02       | 1.63–2.49| < 0.01   | 1.50     | 1.16–1.95 < 0.01 |          |          |
| Number of days in hospital    | 1.04       | 1.03–1.06| < 0.01   | 1.03     | 1.01–1.05 < 0.01 |          |          |
| Age-adjusted Charlson Comorbidity Index |          |          |          |          |              |          |          |
| 0–2                           | 1          |          |          | 1        |              |          |          |
| 3–5                           | 1.98       | 1.55–2.55| < 0.01   | 1.59     | 1.20–2.11 < 0.01 |          |          |
| 6–9                           | 3.68       | 2.55–5.32| < 0.01   | 2.40     | 1.57–3.67 < 0.01 |          |          |
| Clavien-Dindo                 |            |          |          |          |              |          |          |
| 0–3a                          | 1          |          |          | 1        |              |          |          |
| 3b–4                          | 1.61       | 1.10–2.35| < 0.05   | 1.07     | 0.70–1.63 NS  |          |          |

Patients with a stage III colon cancer. Complete case multivariate Cox proportional hazards model (n=690) for disease-free survival

Abbreviation: NS not significant

* Per unit change
patients with a prolonged LOS, even though these variables were associated with a longer LOS. From the results, it is conceivable that a prolonged LOS not only leads to a higher risk but also to early recurrence.

There are some limitations to this study. Despite being conducted in an era where enhanced recovery protocols were internationally recognized, ERAS was not implemented at the studied hospital unit until 2016, perhaps explaining why there was no significant variation in LOS over the period of this study. Furthermore, laparoscopy was rarely carried out in the early years of this material, while almost half of the patients underwent laparoscopic resection at the end of the studied period. The laparoscopic group also had a better outcome in the unadjusted analyses, which might partly be attributed to the fact that they also had a significantly shorter LOS. Nevertheless, other confounding factors involved could simultaneously explain the generally improved oncological outcome in the latter years of the material. For example, during the studied period between 2000 and 2015, the adjuvant treatment regimens have been updated with the addition of oxaliplatin—combined with 5-FU—resulting in fewer combination therapies earlier on in the present study. Likewise, the time from surgery to the initiation of adjuvant chemotherapy has shortened, where more patients received adjuvant chemotherapy within 8 weeks later in the study. Faster turnaround time for the pathology reports and new recommendations of earlier commencement could be two possible explanations for this.

How is the reduced survival rate among patients with a longer postoperative stay explained, if not entirely by increased complications, age, comorbidity, or exclusion from adjuvant treatment? Rather than seeking for an explanation to the provided results, our objective was to evaluate if LOS had prognostic value in itself. One possible mechanism could be related to unidentified tumor immunological factors, where patients with a prolonged LOS have a reduced physical defense against cancer recurrence, perhaps due to inactivity in the postoperative phase which affects the rehabilitation negatively. Patients with prolonged LOS could also be more susceptible to nosocomial infections, which in turn might affect the immunological response. Both experimental and clinical studies on immunosuppression and progression of minimal residual disease in the postoperative phase after cancer surgery supports this theory [26, 27]. However, further studies are warranted to establish a direct causality.

**Conclusions**

In conclusion, this study provides the first comprehensive assessment of postoperative hospital LOS as an independent prognostic factor for DFS among stage III colon cancer patients. In addition, we have demonstrated that patients with a recurrence in their disease had a longer postoperative stay. We believe that LOS represents a patient factor which is associated with DFS regardless of age, comorbidity, postoperative complications, and the initial tumor load. The results from this study could stress the importance of not excluding patients from adjuvant treatment because of prolonged LOS followed by a postponed follow-up. Without providing an explanation for these new discoveries, we recommend that prolonged LOS should be taken into consideration in the risk assessment of stage III colon cancer patients.

**Abbreviations**

- 5-FU: 5-Fluorouracile; CCI: Charlson Comorbidity Index; CRC: Colorectal cancer; DFS: Disease-free survival; ERAS: Enhanced recovery after surgery; FLV: 5-FU and leucovorine; IQR: Interquartile range; LOS: Length of stay; NS: Not significant; OS: Overall survival.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12957-022-02742-8.

Additional file 1: Table S1. Clinical characteristics of stage III colon cancer patients by timing of adjuvant chemotherapy (< 8 weeks or > 8 weeks).

Acknowledgements

We thank L. Munro and B. Sjöberg for the work with the clinical database and J. Flach and M. Åkerstrom for the technical assistance.

Authors’ contributions

G.C. and E.B.L. took part in the study conception and design of this study. F.E., H.T., G.C., D.L., and E.B.L. contributed to the acquisition of the data. Quality control of data and algorithms was done by H.T. and E.B.L. Data analysis and interpretation were performed by FE, H.T., G.C., D.L., and E.B.L. Statistical analysis was done by F.E. and E.B.L. FE performed the manuscript preparation. H.T., G.C., D.L., and E.B.L contributed to manuscript editing and review. The authors read and approved the final manuscript.

Funding

Open access funding provided by University of Gothenburg. This work was supported by grants from the Swedish Cancer Society (CAN 2015/499), the Swedish state under the ALF agreement (ALFGBG-874451), the Swedish state under the ALF agreement (ALFGBG-784211), and DL is supported by grants from the Swedish Cancer Society (CAN 2015/499), the Swedish state under the agreement between the Swedish government and the county councils, and the ALF agreement (ALFGBG-426941). EBL is funded by the Bengt Ihre Foundation and the Swedish state under the ALF agreement (ALFGBG-874451). Open access funding is provided by the University of Gothenburg.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

The patients had given their informed consent for data to be collected for study purposes approved by the Regional Ethical Review Board in Gothenburg (DNR 118–15).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Sahlgrenska Academy at University of Gothenburg, Box 400, 405 30, Gothenburg, Sweden. 2 Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital/Transplant Centre, University of Gothenburg, Gothenburg, Sweden. 3 Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 4 Region Västra Götaland, Department of Surgery, Sahlgrenska University Hospital, 416 85 Gothenburg, Sweden.

Received: 10 June 2022 Accepted: 22 August 2022 Published online: 02 September 2022

References

1. (WHO) WHO: International Agency for Research on Cancer (IARC) - Colon cancer 2020: World Health Organization, 2020 [updated December 2020]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/8-Colon-fact-sheet.pdf.

2. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.

3. Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1291–305.

4. RCC. Nationellt vårdsprogram tjock- och andarrmancer. Regionala cancercentren i samverkan 2020. [Available from: https://kusknapsbanken.cancercentrums.se/diagnoster/tjock-och-andarrmancer/vardprogram/].

5. Kennedy RH, Francis EA, Wharton R, et al. Multicenter randomized controlled trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme. Eur J Clin Oncol. 2014;32:1804–11.

6. Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. JAMA Surg. 2017;152:292–8.

7. Aravanis A, Samy EF, Thomas JD, et al. A retrospective observational study of length of stay in hospital after colorectal cancer surgery in England (1998–2010). Medicine (United States). 2016(95).

8. Orive M, Aguirre U, Gonzalez N, et al. Risk factors affecting hospital stay among patients undergoing colon cancer surgery: a prospective cohort study. Support Care Cancer. 2019;27:4133–44.

9. Des Guetz G, Nicolas P, Perret GY, et al. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer. 2010;46:1049–55.

10. Biagi JJ, Raphael MJ, Mackillop WJ, et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011;305:2335–42.

11. Maletzis G, Mughal A, Currie AC, et al. Factors implicated for delay of adjuvant chemotherapy in colorectal cancer: a meta-analysis of observational studies. Ann Surg Oncol. 2015;22:3799–802.

12. Tarter PI. Postoperative stay associated with prognosis of patients with colorectal cancer. Ann Surg. 1996;223:351–6.

13. Shin JW, Park BK, Kim MJ, et al. Differences in the survival rates of older patients with colorectal cancers in 2003 and 2009. Ann Surg Treatment Res. 2017;92:191–9.

14. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.

15. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.

16. Faiz O, Haji A, Burro E, et al. Hospital stay amongst patients undergoing major elective colorectal surgery: predicting prolonged stay and readmissions in NHS hospitals. Color Dis. 2011;13:816–22.

17. Box ACRK, Van Erning FN, Van Gestel YRM, et al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur J Cancer. 2015;51:2533–61.

18. Law WL, Choi HK, Lee YM, et al. The impact of postoperative complications on long-term prognosis in patients with colorectal cancer. Ann Surg Oncol. 2007;14:2559–66.

19. Aoyama T, Oba K, Honda M, et al. Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients’ data from three large phase III randomized trials. Cancer Med. 2017;6:1573–80.

20. Beck C, Weber K, Brunner M, et al. The influence of postoperative complications in NHS hospitals. Color Dis. 2011;13:816–22.

21. Walker KG, Bell SW, Rickard MJFX, et al. Anastomotic leakage is predictive of diminished survival after potentially curative resection for colorectal cancer. Ann Surg Oncol. 2004;240:255–9.

22. Law WL, Choi HK, Lee YM, et al. Anastomotic leakage is associated with poor long-term outcome in patients after curative colorectal resection for malignancy. J Gastrointest Surg. 2007;11:8–15.

23. Kube R, Mroczkowski P, Granowski D, et al. Anastomotic leakage after colon cancer surgery: a predictor of significant morbidity and hospital mortality, and diminished tumour-free survival. Eur J Surg Oncol. 2010;36:120–4.

24. Saragat M, Thomsen RW, Bossen KS, et al. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5:3–29.
25. Sarfati D, Hill S, Blakely T, et al. The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. BMC Cancer. 2009;9.
26. Goldfarb Y, Sorski L, Benish M, et al. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann Surg. 2011;253:798–810.
27. Kondo E, Koda K, Takiguchi N, et al. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg. 2003;20:445–51.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.